Plain-English translation of NCT07312240 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers are studying several proteins in your blood and spinal fluid that may help explain why ALS affects different people in different ways. By tracking these proteins over time, they hope to better understand disease severity and progression, and eventually help doctors predict outcomes and design better treatments.
ALS progresses very differently in different patients—some decline rapidly, others more slowly. There are currently no reliable tests to predict how quickly someone's disease will worsen or how it will affect them personally. This study aims to find protein signatures in the body that could serve as biological markers to answer these critical questions.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will have a lumbar puncture (spinal tap) to collect cerebrospinal fluid, and blood samples will be drawn. These samples will be analyzed for specific proteins that may help researchers understand your disease. The study is longitudinal, meaning you may be followed over time to track how these protein levels change as your ALS progresses.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
Italy
Sponsor
Istituto Auxologico Italiano
Enrollment target
~140 participants
Started
April 2025
Primary completion
December 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Federico Verde, MD
Istituto Auxologico Italiano
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.